Atorvastatin inhibits functional expression of proatherogenic TLR2 in arterial endothelial cells

Cellular Physiology and Biochemistry

Volumn 28, Issue 4, 2011, Pages 625-630

  Bertocchi, Cristina ^a   Traunwieser, Michaela ^c   Dörler, Jakob ^b   Hasslacher, Julia ^a   Joannidis, Michael ^a   Dunzendorfer, Stefan ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

Atherosclerosis; Inflammation; Statins; Toll like receptors

Indexed keywords

ATORVASTATIN; CASEIN KINASE II; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ARTERY BLOOD FLOW; ARTERY ENDOTHELIUM; ARTICLE; ATHEROGENESIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORONARY ARTERY; DOSE RESPONSE; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 83755183461     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000335758     Document Type: Article

References (25)

1. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003;361:717-725. (Pubitemid 36293625)
2. Gibson FC, Hong C, Chou HH, Yumoto H, Chen J, Lien E, Wong J, Genco CA: Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:2801-2806. (Pubitemid 38737928)
3. Libby P: Inflammation in atherosclerosis. Nature 2002;420:868-874. (Pubitemid 36019640)
4. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145. (Pubitemid 33741967)
5. Tobias P, Curtiss LK: Thematic review series: The immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. J Lipid Res 2005;46:404-411.
6. Mullick AE, Tobias PS, Curtiss LK: Tolllike receptors and atherosclerosis: key contributors in disease and health? Immunol Res 2006;34:193-209.
7. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ: Expression of toll-like receptors in human atherosclerotic lesions: A possible pathway for plaque activation. Circulation 2002;105:1158-1161. (Pubitemid 34225814)
8. Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, Van Middelaar BJ, Pasterkamp G, Quax PH, De Kleijn DP: Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 2004;109:393-398. (Pubitemid 38139309)
9. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M: Lack of Tolllike receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 2004;101:10679-10684. (Pubitemid 38955802)
10. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW: Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004;10:416-421. (Pubitemid 38508522)
11. Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, Feldmann M: Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 2009;120:2462-2469.
12. Michelsen KS, Doherty TM, Shah PK, Arditi M: Role of Toll-like receptors in atherosclerosis. Circ Res 2004;95:e96-e97.
13. Mullick AE, Tobias PS, Curtiss LK: Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005;115:3149-3156. (Pubitemid 41567579)
14. Dunzendorfer S, Lee HK, Tobias PS: Flow-dependent regulation of endothelial Toll-like receptor 2 expression through inhibition of SP1 activity. Circ Res 2004;95:684-691. (Pubitemid 39331928)
15. Mullick AE, Soldau K, Kiosses WB, Bell TA, Tobias PS, Curtiss LK: Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med 2008;205:373-383. (Pubitemid 351281603)
16. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
17. Kravchenko VV, Pan Z, Han J, Herbert JM, Ulevitch RJ, Ye RD: Plateletactivating factor induces NF-kappa B activation through a G protein-coupled pathway. J Biol Chem 1995;270:14928-14934.
18. Rice JB, Stoll LL, Li WG, Denning GM, Weydert J, Charipar E, Richenbacher WE, Miller FJ, Weintraub NL: Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. Arterioscler Thromb Vasc Biol 2003;23:1576-1582. (Pubitemid 37108200)
19. Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, Kapiotis S, Wolzt M: Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004;110:3349-3354. (Pubitemid 39557498)
20. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, Goronzy JJ, Weyand CM, Kopp CW, Huber K, Wolzt M, Wojta J: Simvastatin suppresses endotoxin-induced upregulation of tolllike receptors 4 and 2 in vivo. Atherosclerosis 2006;189:408-413. (Pubitemid 44634488)
21. Methe H, Kim JO, Kofler S, Nabauer M, Weis M: Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005;25:1439-1445. (Pubitemid 40923365)
22. Wang Y, Zhang MX, Meng X, Liu FQ, Yu GS, Zhang C, Sun T, Wang XP, Li L, Wang YY, Ding SF, Yang JM, Zhang Y: Atorvastatin suppresses LPS-induced rapid upregulation of Toll-like receptor 4 and its signaling pathway in endothelial cells. Am J Physiol Heart Circ Physiol 2011;300:H1743-H1752.
23. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G: Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997;185:1951-1958. (Pubitemid 27247081)
24. Haehnel V, Schwarzfischer L, Fenton MJ, Rehli M: Transcriptional regulation of the human toll-like receptor 2 gene in monocytes and macrophages. J Immunol 2002;168:5629-5637. (Pubitemid 34556144)
25. Armstrong SA, Barry DA, Leggett RW, Mueller CR: Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity. J Biol Chem 1997;272:13489-13495. (Pubitemid 27224776)